...
首页> 外文期刊>Pharmaceutical development and technology >Development and evaluation of controlled release ibuprofen matrix tablets by direct compression technique.
【24h】

Development and evaluation of controlled release ibuprofen matrix tablets by direct compression technique.

机译:通过直接压片技术开发和评估控释布洛芬基质片剂。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

This investigation reports the development and evaluation of controlled release ibuprofen matrix tablets. Matrix tablets weighing 400?mg were fabricated by directly compressing ibuprofen (100?mg) with Eudragit RSPO and Avicel PH 101. The release of ibuprofen was dependant on concentration of Eudragit in the formulation. Varying Eudragit concentration from 10-50% of the formulation (in increments of 5%) revealed that in 4?h, tablets containing 50% Eudragit released about 40% ibuprofen compared to 100% released from tablets containing 10% Eudragit. Following analysis of release mechanism using various models available in literature, release of ibuprofen from matrix tablets was dominated by polymer diffusion-controlled mechanism at least for first 4?h. Thereafter, the release mechanism became more complicated and lost controlled release by diffusion due to change of tablet integrity, such as erosion of polymer matrix. In conclusion, controlled release ibuprofen matrix tablets with desired drug release rate can be fabricated by various formulation variables with direct compression technique.
机译:这项研究报告了控释布洛芬基质片剂的开发和评估。通过直接用Eudragit RSPO和Avicel PH 101压制布洛芬(100毫克)制得重达400毫克的基质片剂。布洛芬的释放取决于制剂中Eudragit的浓度。从制剂的10%至5​​0%改变Eudragit浓度(以5%为增量)表明,在4?h内,含有50%Eudragit的片剂释放出约40%布洛芬,而从含有10%Eudragit的片剂中释放出100%。使用文献中可用的各种模型分析释放机理后,布洛芬从基质片中的释放至少在最初的4?h内受聚合物扩散控制的机理支配。此后,由于片剂完整性的改变,例如聚合物基质的侵蚀,释放机理变得更加复杂并且由于扩散而失去了受控的释放。总之,可以通过直接压制技术通过各种制剂变量来制备具有所需药物释放速率的控释布洛芬基质片剂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号